Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

4.41USD
21 Sep 2018
Change (% chg)

$-0.10 (-2.22%)
Prev Close
$4.51
Open
$4.52
Day's High
$4.52
Day's Low
$4.35
Volume
234,162
Avg. Vol
116,501
52-wk High
$5.13
52-wk Low
$1.79

Chart for

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $313.49
Shares Outstanding(Mil.): 71.09
Dividend: --
Yield (%): --

Financials

  MEIP.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.92 -- --
ROI: -54.29 1.50 12.72
ROE: -79.11 0.19 14.85

BRIEF-MEI Pharma And Helsinn Announce Positive Results In Myelodysplastic Syndrome Trial

* MEI PHARMA AND HELSINN GROUP ANNOUNCE SUCCESSFUL INTERIM ANALYSIS OF PRACINOSTAT/AZACITIDINE PHASE 2 COMBINATION STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS

May 31 2018

BRIEF-Growth Equity Opportunities Fund V LLC Reports 9.99 Pct Stake In MEI Pharma Inc

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 9.99 PERCENT STAKE IN MEI PHARMA INC AS OF MAY 16 - SEC FILING Source text: (https://bit.ly/2IHP4lE) Further company coverage:

May 23 2018

BRIEF-MEI Pharma Announces $75 Mln Private Placement

* MEI PHARMA INC - PROCEEDS FROM FINANCING WILL BE USED TO FUND CONTINUED CLINICAL DEVELOPMENT OF MEI-401

May 14 2018

BRIEF-MEI Pharma Q3 Loss Per Share $0.16

* Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S

May 09 2018

Earnings vs. Estimates